Indefinite Delivery Contract HHSO100200600016I
Award Date
7/14/06
Last Date to Order
9/1/10
Funding Federal Agency
Immediate Office of the Secretary
Contracting Federal Agency
Office of the Assistant Secretary for Preparedness and Response
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The provided information describes an Indefinite Delivery Contract (IDC) awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Roche Laboratories Inc. The IDC, with a ceiling value of $131,245,722.23, is for the acquisition of the antiviral drug Tamiflu to support a public health emergency response to a pandemic. The contract was awarded on June 29, 2006, with a period of performance through September 1, 2010. This...
This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian federal agency, to Glaxosmithkline, LLC, a pharmaceutical company, to provide a portfolio of new antibacterial drugs for hospital and biothreat pathogens. The single-award IDC has a ceiling value of $255,851,502.87 and a period of performance through September 30, 2029. The contract aims to procure a range of pharmaceutical products and services from...
This indefinite delivery contract (IDC) was awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Seqirus Inc., a division of the global biotechnology company CSL Seqirus. The $13.4 billion IDC serves as the primary mechanism for Seqirus to rapidly provide medical countermeasures (MCMs) such as vaccines and adjuvants for pandemic preparedness and response. Under this IDC, HHS ASPR has issued numerous task orders...
The indefinite delivery contract (IDC) 75D30120D08572 was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC for the provision of vaccines for adults. The $131,225,875 multiple award contract has a period of performance through June 30, 2021. Glaxosmithkline, a pharmaceutical company, will supply a range of vaccines and antiviral medications to support disease prevention efforts, immunization programs, and healthcare services for various U.S. government...
This Indefinite Delivery Contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Ansun Biopharma, Inc. The contract's purpose is to procure a broad-spectrum antiviral therapeutic for the treatment of influenza A and B virus infections. The total ceiling value of the contract is $19,112,357.63, and the period of performance runs from the award date of September 29, 2012 through the ultimate completion date of February 28, 2014. This...
This indefinite delivery contract, awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), has a ceiling value of $4,687,707,199. The purpose is to provide medical countermeasures such as vaccines and adjuvants for pandemic preparedness and response or in response to a public health emergency designated by HHS. The prime contractor is Glaxosmithkline, LLC, a pharmaceutical company that...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency, to Glaxosmithkline Holdings (Americas) Inc. as the prime contractor. The contract has a ceiling value of $261,469,025.27 and a period of performance ending on June 30, 2011. The purpose of this IDC is to provide adult vaccines, as part of the CDC's Adult Vaccine Contract 2010 - 2011 program. The contract was not set aside for any specific business category. It was...
The federal contract IDV award is an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian federal agency, to Glaxosmithkline Holdings (Americas) Inc. The contract, identified as HHSD200200930521I, has a ceiling value of $809,252,070.00 and a period of performance from July 1, 2009 to June 30, 2010. The contract, known as VFA 2009, does not have any set-asides and was awarded as a multiple-award vehicle....
This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the U.S. Department of Health and Human Services (HHS). The IDC has a ceiling value of $44,440,563.00 and a period of performance from September 2, 2015 to September 30, 2023. The primary purpose of this IDC is to support the development of Regeneron's anti-Ebola antibody therapeutics program. Regeneron Pharmaceuticals Inc., a for-profit...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to the pharmaceutical company Glaxosmithkline, LLC to provide pediatric influenza vaccines for the 2024-2025 timeframe. The contract has a ceiling value of $182,592,000 and a period of performance through February 28, 2025. Glaxosmithkline, a foreign-owned for-profit organization, has extensive experience as a prime contractor providing a range of pharmaceutical products and services to...